TORONTO / Nov 25, 2025 / Business Wire / Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will participate in the following investor conferences: Piper Sandler 37th Annual Healthcare Conference (New York, NY) Date: Wednesday, Dec. 3, 2025 Time: 12:50 p.m.... Read More

Research confirms muscle stem cell dysfunction impairs polarity and impedes production of myogenic progenitors during fetal development Findings solidify AAK1 as a paradigm shifting drug target to restore muscle repair and regeneration in Duchenne muscular dystrophy Publication available here TORONTO / Nov 18, 2025 / Business Wire / Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a... Read More

Appointed Mark Nawacki, seasoned M&A expert, co-founder, president & former CEO of Searchlight Pharma, to Board of Directors Completed IND submission to the U.S. FDA and global regulatory filings to advance a Phase 2 clinical trial of SAT-3247 in children with Duchenne muscular dystrophy (DMD) Dosed first patient in open-label, long-term follow-up study (LT-001) of SAT-3247 in adults with DMD Ended the third quarter of 2025... Read More

TORONTO / Oct 30, 2025 / Business Wire / Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that its leadership team will present and participate in the following investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference Date: Monday, Nov. 10, 2025... Read More

First returning adult patient from Phase 1b study recently dosed; additional returning patients being scheduled 11-month open-label study will evaluate functional outcomes, safety, muscle composition by MRI, and serum biomarkers Results following initial 3 months of treatment anticipated in early 2026, quarterly thereafter Planning underway to broaden LT-001 study protocol to enroll new adult patients in Australia and open... Read More

Adults with Duchenne muscular dystrophy demonstrated functional improvements exceeding natural history, following 28-day treatment with SAT-3247 Grip strength increased 118.6% and predicted forced vital capacity increased 5.8%; whereas, both decline in natural history SAT-3247 demonstrated safety, tolerability, and expected pharmacokinetics (PK) across all parts of Phase 1 a/b study New data presented in late-breaking poster... Read More

TORONTO / Sep 29, 2025 / Business Wire / Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will present two scientific posters at the 30th Annual Congress of the World Muscle Society (WMS), taking place Oct. 7–11, 2025, in Vienna, Austria. Data being... Read More

Regulatory submissions filed in the U.S., UK, Europe, Serbia and Australia Three-month randomized placebo-controlled study to assess safety, pharmacokinetics, dose, muscle biopsies, and measures of function in ambulatory children First patient expected to be enrolled into the study by the end of 2025 Long-term extension study approved in Australia with adult patients from the Phase 1b trial; additional adult patients also... Read More

TORONTO / Aug 21, 2025 / Business Wire / Satellos Bioscience Inc . (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, announced today that members of its senior management team will participate in the following investor events in September: Wells Fargo Healthcare Conference Format: Participation in 1x1... Read More

Reported positive Phase 1b data in five adults with Duchenne muscular dystrophy (DMD) after 28 days of treatment Demonstrated safety, tolerability and an approximate doubling in grip strength On track to initiate a follow-up of the Phase 1b study in adults with DMD in Q3 2025 Expected to report 3-month interim data this year Preparing submissions to enable initiation of a global Phase 2 randomized, placebo-controlled... Read More

TORONTO / Aug 05, 2025 / Business Wire / Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company” ), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will present at the Canaccord Genuity’s 45th Annual Growth Conference, taking place Aug. 13–14, 2025, at the InterContinental Boston. Satellos management will present on Wed., Aug. 13, from... Read More

Brings a successful track record in clinical development and regulatory approval of innovative neuromuscular therapies TORONTO / Jul 16, 2025 / Business Wire / Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases, today announced the appointment of Wildon Farwell, M.D., MPH, as... Read More

TORONTO / Jun 18, 2025 / Business Wire / Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the results of its Annual and Special Meeting of Shareholders held June 18, 2025 (the “ Meeting ”). Satellos is pleased to announce that all the nominees... Read More

TORONTO / Jun 18, 2025 / Business Wire / Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced the election of Iris Loew-Friedrich, M.D., Ph.D., and Selwyn Ho, MBBS, to its Board of Directors. “I am so excited to welcome Dr. Loew-Friedrich and Dr. Ho... Read More

TORONTO / Jun 16, 2025 / Business Wire / Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced its participation in the 2025 Parent Project Muscular Dystrophy (PPMD) Annual Conference, taking place June 19–21 in Las Vegas, Nevada. The PPMD Annual... Read More

Phase 1b data shows treatment with SAT-3247 was safe and well-tolerated Pharmacokinetic (PK) profile of SAT-3247 translated as expected to Duchenne Muscular Dystrophy (DMD) patients taking concurrent steroids Potential trend to improved grip strength observed, with average strength across the study participants doubling from ~2kg to ~4kg Study participants will have the option to enroll into an 11-month, long-term follow-up... Read More

Toronto, Ontario--(Newsfile Corp. - May 20, 2025) - Bloom Burton & Co. Inc. (Bloom Burton) announces that, today, it exercised 3,200,000 common share purchase warrants (Warrants) of Satellos Bioscience Inc. (Corporation) at $0.50 per share for aggregate consideration of $1,600,000, and the remaining 3,360,474 unexercised Warrants expired. This resulted in a decrease of beneficial holdings to under 10%, requiring the filing... Read More

Completed enrollment in the Phase 1b trial in adult patients with Duchenne muscular dystrophy (DMD); data analysis and reporting expected in Q2 2025 Received regulatory approval, allowing initiation of a long-term follow-up study to treat DMD patients from the Phase 1b for 11 additional months Profile of SAT-3247, presented at the Muscular Dystrophy Association (MDA) Conference, demonstrated the drug to be safe and well... Read More

TORONTO / May 07, 2025 / Business Wire / Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company” ), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will present at the CureDuchenne FUTURES National Conference, taking place in San Antonio, TX, from May 22 to 25. Satellos Co-founder and CEO Frank Gleeson will participate in the “New... Read More

TORONTO / Apr 29, 2025 / Business Wire / Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company” ), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will present at the 2025 Bloom Burton & Co. Healthcare Investor Conference taking place in Toronto on May 5 and 6. Satellos Co-founder and CEO Frank Gleeson will provide a presentation on... Read More

TORONTO / Apr 02, 2025 / Business Wire / Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company” ), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will present and participate at the following investor conferences in April: Oppenheimer Innovation on the Island Format: Presentation Date: Thurs., April 10, 2025, 10:08 a.m. AST Location:... Read More

Completed enrollment and dosing in a Phase 1a clinical trial in 72 healthy volunteers to assess safety and pharmacokinetic (PK) properties of SAT-3247 Presented initial Phase 1a data at Muscular Dystrophy Association (MDA) Clinical & Scientific Conference showing SAT-3247 was safe, well-tolerated and showed the intended PK profile after both single- and repeated-dose administration Initiated enrollment in a Phase 1b clinical... Read More

Phase 1a data shows SAT-3247 was safe and well tolerated in 72 healthy volunteers after both single and repeated administration Phase 1a data shows favorable pharmacokinetic (PK) profile of SAT-3247, reinforcing its potential as a first-of-its-kind oral therapy for Duchenne Muscular Dystrophy (DMD) Enrollment and treatment are ongoing in the Phase 1b trial in adults with DMD TORONTO / Mar 19, 2025 / Business Wire / Satellos... Read More

Satellos plans to highlight Phase 1 safety and PK data for SAT-3247 TORONTO / Feb 18, 2025 / Business Wire / Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced an oral presentation at the upcoming 2025 Muscular Dystrophy Association (MDA)... Read More

Company remains on track to report Phase 1a data from both the Single- and Multiple-Ascending Dose (SAD and MAD) cohorts in the healthy volunteer portion of the study in 1Q 2025 at an upcoming major medical meeting The Phase 1b portion of the trial, in DMD patients, is underway with the intention of enrolling up to 10 adult volunteers with genetically confirmed DMD during 1Q 2025 Phase 2 IND filing on track to be submitted... Read More

TORONTO / Feb 04, 2025 / Business Wire / Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will present at and participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference taking place virtually February... Read More

TORONTO / Dec 20, 2024 / Business Wire / Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced that it has closed an equity offering, issuing a total of 63,285,000 equity securities for gross proceeds of approximately $57 million (USD$40... Read More

BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS ON SEDAR+ TORONTO / Dec 17, 2024 / Business Wire / Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, is pleased to announce the pricing and terms of... Read More

BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS ON SEDAR+ TORONTO / Dec 16, 2024 / Business Wire / Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that it has filed a preliminary... Read More

Marks successful completion of full enrollment of SAD cohorts and the first two MAD cohorts in the healthy volunteer study Up to 10 adult participants with genetically confirmed Duchenne Muscular Dystrophy (“DMD”) to be enrolled in the now ongoing Phase 1b trial in DMD patients Phase 1 data to be presented at major medical conference in Q1 2025 TORONTO / Dec 11, 2024 / Business Wire / Satellos Bioscience Inc. (TSX: MSCL,... Read More

TORONTO / Dec 03, 2024 / Business Wire / Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) (“ Satellos ” ) , a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that Frank Gleeson, Co-founder and CEO will participate in Oppenheimer’s Movers in Rare Disease Summit taking place in New York City on December 12, 2024.... Read More

TORONTO / Dec 02, 2024 / Business Wire / Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) (" Satellos " or the " Company "), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced participation in a live investor webinar (the "Webinar") focused on a discussion of Duchenne muscular dystrophy ("DMD") by Key Opinion Leaders... Read More

TORONTO / Nov 14, 2024 / Business Wire / Satellos Bioscience Inc. (TSX: MSCL) (OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the appointment of Stephanie Brown to its Board of Directors. Ms. Brown brings over 30 years of biopharma industry experience, having held numerous... Read More

Completed enrollment for SAT-3247 in Duchenne muscular dystrophy (DMD) in the first three (of five) single-ascending dose (SAD) cohorts with no safety concerns and initiated enrollment of first multiple-ascending-dose (MAD) cohort Presented canine data for SAT-3247 at the 2024 World Muscle Society Annual Congress showing improved measures of strength reaching near normal levels Cash balance of $23.4 million as of September... Read More

TORONTO / Nov 04, 2024 / Business Wire / Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that members of the management team of the Company will participate in the following investor conferences. Guggenheim Securities Healthcare Innovation... Read More

Analysis showed improvement in muscle morphology and increased levels of regeneration in muscle groups, including the diaphragm, quadriceps, and calf No adverse events and no significant changes in hematology or clinical chemistry were observed after four months of daily, oral treatment with SAT-3247, Satellos’ proprietary small molecule Data to be presented at the 2024 World Muscle Society Annual Congress TORONTO / Oct 01,... Read More

The first healthy volunteer has been dosed in the first component of the Phase 1 study Initial safety and pharmacokinetic data expected in Q4 2024 Initiation of the second component of the Phase 1 study, in adult DMD patients, expected in Q1 2025 TORONTO / Sep 18, 2024 / Business Wire / Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule... Read More

TORONTO / Sep 05, 2024 / Business Wire / Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that Mr. Frank Gleeson, Co-founder and CEO of Satellos will participate in fireside chats and one-on-one meetings during the following conferences... Read More

Dosing of first participant in a Phase 1 clinical trial of SAT-3247 anticipated in Q3 2024 TORONTO / Aug 19, 2024 / Business Wire / Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced acceptance of a clinical research proposal to a Human... Read More

Updated data in a canine model of Duchenne muscular dystrophy (DMD) show further increased improvement in muscle force over baseline of 195% at four-month point Receipt of Orphan Drug and Rare Pediatric Disease designations from US FDA On track to dose first participant in Phase 1 clinical trial with SAT-3247 in Q3 2024 Cash balance of $27.7 million at June 30, 2024 TORONTO / Aug 12, 2024 / Business Wire / Satellos... Read More

SAT-3247 is a proprietary, oral small molecule drug being developed by Satellos as a novel treatment to regenerate skeletal muscle which is lost in Duchenne muscular dystrophy (DMD) DMD is a rare genetic disorder characterized by progressive muscle degeneration and weakness Satellos has also received Orphan Drug Designation from the FDA for SAT-3247 Initiation of a Phase 1 clinical trial of SAT-3247 anticipated in Q3 2024... Read More

Investigational New Drug (IND) enabling preclinical and toxicology studies successfully completed Initiation of a Phase 1 clinical trial of SAT-3247 anticipated in Q3 2024 TORONTO / Jul 11, 2024 / Business Wire / Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and... Read More

SAT-3247 treatment improved muscle repair and regeneration in canine model of DMD SAT-3247 treatment also improved muscle force in this canine model of DMD Satellos remains on track to initiate a Phase 1 clinical trial in Q3 2024 TORONTO / Jul 02, 2024 / Business Wire / Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic... Read More

Frank Gleeson, Satellos CEO, to participate in a panel discussion titled "Research Row: PPMD Moving the Needle" on June 29, 2024 TORONTO / Jun 27, 2024 / Business Wire / Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced that Frank Gleeson,... Read More

Satellos expects to begin first-in-human clinical trials mid-year for SAT-3247, an oral small molecule drug candidate in development as a novel regenerative medicine approach to treating DMD TORONTO / May 28, 2024 / Business Wire / Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle... Read More

TORONTO / May 14, 2024 / Business Wire / Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the results of its Annual and Special Meeting of Shareholders held today, May 14, 2024 (the “Meeting”). Satellos is pleased to announce that all of... Read More

Conducted preclinical toxicology studies and GMP manufacturing of SAT-3247 On track to initiate Phase 1 first-in-human clinical trials mid-2024 Cash balance of $33.2 million at March 31, 2024 Invited to present at PPMD 30 th annual conference to be held June 26-29, 2024 TORONTO / May 14, 2024 / Business Wire / Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a public biotech company... Read More

TORONTO / Apr 08, 2024 / Business Wire / Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will present at and participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference taking place April 16th and 17th in... Read More

Engaged CRO for first-in-human SAT-3247 Phase 1 clinical study Initiated GLP toxicity studies and GMP manufacturing of SAT-3247 Continues to be on track to initiate first-in-human clinical trials mid-2024 Cash balance of $39.6 million as at December 31, 2023 TORONTO / Mar 27, 2024 / Business Wire / Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a regenerative medicine company aimed at... Read More

TORONTO / Mar 14, 2024 / Business Wire / Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that Frank Gleeson, cofounder and CEO of Satellos, will present at the following investor conferences: Stifel 2024 Virtual CNS Days Format: Fireside... Read More

TORONTO / Mar 05, 2024 / Business Wire / Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that members from Satellos’ management team will host investor meetings at the Leerink Partners Global Biopharma Conference 2024 being held from Monday,... Read More

- Orally administered SAT-3247 demonstrates efficacy across three mouse models of muscle degeneration - Efficacy in muscle injury model demonstrates broad potential of SAT-3247 TORONTO / Mar 04, 2024 / Business Wire / Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and... Read More

TORONTO / Feb 21, 2024 / Business Wire / Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that it has been named as one of the top performers on the TSX Venture Exchange. The 2024 TSX Venture 50 celebrates the strongest performance on the TSX Venture... Read More

TORONTO / Feb 20, 2024 / Business Wire / Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced a late-breaking oral presentation and a poster presentation at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being... Read More

TORONTO / Feb 14, 2024 / Business Wire / Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that its common shares will commence trading on the Toronto Stock Exchange (“TSX”) as of the opening of trading tomorrow under the Company’s current... Read More

TORONTO / Jan 16, 2024 / Business Wire / Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, is pleased to announce that it has received conditional approval from the Toronto Stock Exchange (“TSX”) to graduate from the TSX Venture Exchange (the “TSXV”) and to... Read More

Company disclosed drug target for Duchenne program; remains on track to initiate clinical trials mid-2024 Satellos appointed Michael Cross, PhD, MBA, as Chief Business Officer and other key leadership team members including Chief Financial Officer and Senior Vice President, Clinical Operations Cash balance at September 30, 2023, of $44.3 million provides runway through 2025 TORONTO / Nov 22, 2023 / Business Wire / Satellos... Read More

TORONTO / Nov 20, 2023 / Business Wire / Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will present and participate in the Piper Sandler 35 th Annual Healthcare Conference taking place November 28-30 in New York City. Mr.... Read More

The drug target for the Duchenne program is AAK1, a protein kinase in the Notch pathway, which the Company discovered can be modulated to enable muscle regeneration Satellos is conducting IND-enabling studies and GMP manufacturing, nominates SAT-3247 as lead drug candidate, files patent applications for its drug target and drug development candidates, and remains on track to initiate clinical development in mid-2024 The... Read More

TORONTO / Nov 02, 2023 / Business Wire / Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will present and participate in the Stifel 2023 Healthcare Conference taking place November 14 and 15 in New York City. Mr. Frank... Read More

Toronto, Ontario--(Newsfile Corp. - September 20, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will participate in the Cantor Fitzgerald Global Healthcare Conference 2023 taking place September 26 - 28 in New... Read More

Toronto, Ontario--(Newsfile Corp. - September 7, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that it has entered into an agreement with ICP Securities Inc. ("ICP"), a dealer member in good standing with the Canadian Investment... Read More

Elizabeth Williams, CPA, CA, joins as CFO, bringing extensive expertise leading corporate finance and strategy for public biotech companies listed on Nasdaq and TSX. Current CFO, Warren Whitehead, CPA, CMA, transitions to Head of Corporate Strategy to focus on strengthening and expanding collaborations and partnerships. Satellos is advancing a potentially first-in-class small molecule drug candidate to clinical trials for... Read More

$48.7 million in cash and cash equivalents at June 30, 2023, providing expected runway to advance Company's development candidate ("DC") through Phase I clinical development in healthy human volunteers and Duchenne muscular dystrophy patients Toronto, Ontario--(Newsfile Corp. - August 29, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small... Read More

Company also recently received Rare Pediatric Disease Designation from the FDA for SAT-3153 for the treatment of pediatric patients with Duchenne Toronto, Ontario--(Newsfile Corp. - August 2, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating muscle diseases and... Read More

Toronto, Ontario--(Newsfile Corp. - June 30, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today the results of its annual general meeting of shareholders held virtually on June 29, 2023 (the "Meeting"), as well as the adoption of amendments to the Company's... Read More

Dr. Alan K. Jacobs joins Satellos as CMO on June 7th, 2023 Toronto, Ontario--(Newsfile Corp. - June 7, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (" Satellos " or the " Company "), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today the appointment of Alan K. Jacobs, MD as Chief Medical Officer (CMO) of the Company, effective June... Read More

Toronto, Ontario--(Newsfile Corp. - June 1, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (" Satellos " or the " Company "), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, today announced that its board of directors (the "Board") has approved grants of stock options (the " Stock Options ") pursuant to the terms of the Company's Stock Option Plan.... Read More

$55 million equity financing closed Resourced to advance lead drug candidate into clinical trials Toronto, Ontario--(Newsfile Corp. - May 30, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (" Satellos " or the " Company "), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today its financial results and operational highlights for the three... Read More

Toronto, Ontario--(Newsfile Corp. - May 17, 2023) - Bloom Burton & Co. Inc. announces that, today, it and its affiliate acquired 1,453,070 common shares (Shares) and 6,636,734 compensation options (Compensation Options) of Satellos Bioscience Inc. (Corporation) in connection with a public offering of the Corporation by way of a short form prospectus dated May 9, 2023. Bloom Burton purchased the Shares at a price of $0.50 per... Read More

Toronto, Ontario--(Newsfile Corp. - May 17, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (" Satellos " or the " Company "), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, today announced that it has closed an equity offering, issuing a total of 110 million equity securities for gross proceeds of $55 million (the " Offering "). The Offering... Read More

Toronto, Ontario--(Newsfile Corp. - May 10, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (" Satellos " or the " Company "), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce today that it has filed its final short form prospectus (the " Prospectus ") with the securities regulatory authorities in the Provinces of British... Read More

Toronto, Ontario--(Newsfile Corp. - April 19, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (" Satellos " or the " Company "), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce the pricing and terms of its previously announced best efforts public offering of common shares of the Company (" Common Shares ") (or pre-funded... Read More

Toronto, Ontario--(Newsfile Corp. - April 18, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (" Satellos " or the " Company "), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today that it has filed a preliminary short form prospectus (the " Preliminary Prospectus ") with the securities regulatory authorities in the Provinces of British... Read More

Toronto, Ontario--(Newsfile Corp. - March 30, 2023) - Satellos Bioscience Inc. ( TSXV: MSCL ) ( OTCQB: MSCLF ) (" Satellos " or the " Company "), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, announced today its financial results and operational highlights for the year ending December 31, 2022. All dollar... Read More

Toronto, Ontario--(Newsfile Corp. - March 29, 2023) - Satellos Bioscience Inc. ( TSXV: MSCL ) ( OTCQB: MSCLF ) (" Satellos " or the " Company "), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, today announced it has closed its previously announced non-brokered private placement offering of 10% unsecured... Read More

Toronto, Ontario--(Newsfile Corp. - March 22, 2023) - Satellos Bioscience Inc. ( TSXV: MSCL ) ( OTCQB: MSCLF ) (" Satellos " or the " Company "), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, previously announced on March 15, 2023 a proposed non-brokered private placement offering (the " Offering ") of... Read More

Ryan Mitchell, PhD and Director of Business Development at Satellos to highlight SAT-3153 and Satellos' novel muscle regeneration technology in two forums at this year's MDA Conference and Summit Toronto, Ontario--(Newsfile Corp. - March 17, 2023) - Satellos Bioscience Inc. ( TSXV: MSCL ) ( OTCQB: MSCLF ) (" Satellos " or the " Company "), a drug discovery company developing small molecule therapeutics to regenerate muscle... Read More

Toronto, Ontario--(Newsfile Corp. - March 15, 2023) - Satellos Bioscience Inc. ( TSXV: MSCL ) ( OTCQB: MSCLF ) (" Satellos " or the " Company "), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, today announced a proposed non-brokered private placement offering of 10% unsecured non-convertible debenture... Read More

Toronto, Ontario--(Newsfile Corp. - March 10, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) (" Satellos " or the " Company "), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, is pleased to announce additional results from further preclinical studies using the Company's lead drug candidate... Read More

40% increase in muscle size compared to control mice 25% increase in muscle force, approaching levels seen in normal mice Toronto, Ontario--(Newsfile Corp. - February 6, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) (" Satellos " or the " Company "), a drug discovery company developing small molecule... Read More

SAT-3153 Designated for pre-IND Studies Toronto, Ontario--(Newsfile Corp. - January 3, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) (" Satellos " or the " Company "), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, is pleased to announce that it has designated SAT-3153 for development... Read More

Satellos Bioscience Inc. (TSXV: MSCL) (" Satellos " or the " Corporation "), a drug discovery company developing therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, announced today its financial results and operational highlights for the quarter ending September 30, 2022. The Company's interim condensed consolidated financial statements for the quarter ended... Read More